The role of soluble CD40L in immunosuppression

We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlom, Jeffrey, Jochems, Caroline, Gulley, James L., Huang, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583923/
https://www.ncbi.nlm.nih.gov/pubmed/23483661
http://dx.doi.org/10.4161/onci.22546
_version_ 1782475507252592640
author Schlom, Jeffrey
Jochems, Caroline
Gulley, James L.
Huang, Jianping
author_facet Schlom, Jeffrey
Jochems, Caroline
Gulley, James L.
Huang, Jianping
author_sort Schlom, Jeffrey
collection PubMed
description We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumor-targeting vaccines or other therapeutic modalities.
format Online
Article
Text
id pubmed-3583923
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35839232013-03-11 The role of soluble CD40L in immunosuppression Schlom, Jeffrey Jochems, Caroline Gulley, James L. Huang, Jianping Oncoimmunology Author's View We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumor-targeting vaccines or other therapeutic modalities. Landes Bioscience 2013-01-01 /pmc/articles/PMC3583923/ /pubmed/23483661 http://dx.doi.org/10.4161/onci.22546 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Schlom, Jeffrey
Jochems, Caroline
Gulley, James L.
Huang, Jianping
The role of soluble CD40L in immunosuppression
title The role of soluble CD40L in immunosuppression
title_full The role of soluble CD40L in immunosuppression
title_fullStr The role of soluble CD40L in immunosuppression
title_full_unstemmed The role of soluble CD40L in immunosuppression
title_short The role of soluble CD40L in immunosuppression
title_sort role of soluble cd40l in immunosuppression
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583923/
https://www.ncbi.nlm.nih.gov/pubmed/23483661
http://dx.doi.org/10.4161/onci.22546
work_keys_str_mv AT schlomjeffrey theroleofsolublecd40linimmunosuppression
AT jochemscaroline theroleofsolublecd40linimmunosuppression
AT gulleyjamesl theroleofsolublecd40linimmunosuppression
AT huangjianping theroleofsolublecd40linimmunosuppression
AT schlomjeffrey roleofsolublecd40linimmunosuppression
AT jochemscaroline roleofsolublecd40linimmunosuppression
AT gulleyjamesl roleofsolublecd40linimmunosuppression
AT huangjianping roleofsolublecd40linimmunosuppression

Ejemplares similares